Highland Peak Capital LLC Has $5.85 Million Stake in Grifols, S.A. (NASDAQ:GRFS)

Highland Peak Capital LLC grew its holdings in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 29.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 786,210 shares of the biotechnology company's stock after purchasing an additional 179,114 shares during the quarter. Grifols makes up approximately 3.2% of Highland Peak Capital LLC's portfolio, making the stock its 11th largest holding. Highland Peak Capital LLC owned 0.11% of Grifols worth $5,849,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in GRFS. Raymond James Financial Inc. bought a new position in Grifols during the 4th quarter worth approximately $91,000. Charles Schwab Investment Management Inc. grew its holdings in Grifols by 5.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after buying an additional 1,657 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Grifols by 344.4% in the 4th quarter. Blue Trust Inc. now owns 8,697 shares of the biotechnology company's stock valued at $65,000 after buying an additional 6,740 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Grifols by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company's stock worth $192,000 after purchasing an additional 2,403 shares in the last quarter. Finally, R Squared Ltd bought a new position in Grifols in the fourth quarter valued at approximately $28,000.

Analysts Set New Price Targets

Separately, Morgan Stanley initiated coverage on shares of Grifols in a report on Wednesday, February 12th. They issued an "overweight" rating for the company.

Remove Ads

Grifols Stock Down 0.5 %

GRFS stock traded down $0.04 during midday trading on Thursday, hitting $7.72. The stock had a trading volume of 1,086,131 shares, compared to its average volume of 1,294,489. The firm has a market cap of $5.31 billion, a price-to-earnings ratio of 6.60 and a beta of 0.35. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 52-week low of $5.68 and a 52-week high of $9.96. The business has a 50-day moving average of $7.49 and a two-hundred day moving average of $8.15.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.